ATE435034T1 - Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist. - Google Patents

Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.

Info

Publication number
ATE435034T1
ATE435034T1 AT99940868T AT99940868T ATE435034T1 AT E435034 T1 ATE435034 T1 AT E435034T1 AT 99940868 T AT99940868 T AT 99940868T AT 99940868 T AT99940868 T AT 99940868T AT E435034 T1 ATE435034 T1 AT E435034T1
Authority
AT
Austria
Prior art keywords
hiv
neutralizing antibody
characterization
expression
antibody response
Prior art date
Application number
AT99940868T
Other languages
German (de)
English (en)
Inventor
Gerald Quinnan
Peng Fei Zhang
Original Assignee
Jackson H M Found Military Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson H M Found Military Med filed Critical Jackson H M Found Military Med
Application granted granted Critical
Publication of ATE435034T1 publication Critical patent/ATE435034T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99940868T 1998-08-04 1999-08-04 Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist. ATE435034T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9526798P 1998-08-04 1998-08-04
PCT/US1999/017596 WO2000007631A1 (en) 1998-08-04 1999-08-04 Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response

Publications (1)

Publication Number Publication Date
ATE435034T1 true ATE435034T1 (de) 2009-07-15

Family

ID=22251048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940868T ATE435034T1 (de) 1998-08-04 1999-08-04 Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.

Country Status (7)

Country Link
EP (1) EP1104310B1 (enExample)
JP (1) JP4637356B2 (enExample)
AT (1) ATE435034T1 (enExample)
AU (1) AU762376C (enExample)
CA (1) CA2338886C (enExample)
DE (1) DE69941051D1 (enExample)
WO (1) WO2000007631A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW511388B (en) 2000-03-28 2002-11-21 Koninkl Philips Electronics Nv Passive radiator having mass elements
CA2483870A1 (en) * 2002-05-10 2004-06-03 The Henry M. Jackson Foundation Interacting site for gp41 on gp120 of hiv-1
WO2004113370A1 (de) 2003-06-20 2004-12-29 Dade Behring Marburg Gmbh NEUE OBERFLÄCHENPROTEIN-(HBsAG-) VARIANTE DES HEPATITIS B VIRUS
ATE552264T1 (de) * 2003-06-20 2012-04-15 Siemens Healthcare Diagnostics Neue oberflächenprotein- (hbsag-) variante des hepatitis b virus
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
JP2009536653A (ja) * 2006-05-09 2009-10-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｈｉｖ−１免疫原性組成物
US8597658B2 (en) * 2007-11-12 2013-12-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. HIV-1 envelope glycoprotein oligomer and methods of use
EP2552480A1 (en) 2010-03-26 2013-02-06 GlaxoSmithKline Biologicals S.A. Hiv vaccine
US20130280322A1 (en) 2010-09-27 2013-10-24 Glaxosmithkline Biologicals S.A. Vaccine
EP2892554B1 (en) 2012-09-07 2020-08-26 Emory University Hiv immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820865A (en) * 1988-01-26 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
EP0586505A1 (en) * 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE570357T1 (de) * 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
GB9318901D0 (en) * 1993-09-13 1993-10-27 Centre Nat Rech Scient Multiple branch peptide construction

Also Published As

Publication number Publication date
EP1104310A1 (en) 2001-06-06
CA2338886C (en) 2011-10-04
AU762376C (en) 2004-10-14
WO2000007631A9 (en) 2000-11-16
AU5464299A (en) 2000-02-28
DE69941051D1 (de) 2009-08-13
EP1104310B1 (en) 2009-07-01
EP1104310A4 (en) 2003-01-08
CA2338886A1 (en) 2000-02-17
WO2000007631A1 (en) 2000-02-17
AU762376B2 (en) 2003-06-26
JP2002522039A (ja) 2002-07-23
JP4637356B2 (ja) 2011-02-23

Similar Documents

Publication Publication Date Title
NZ237666A (en) Hiv envelope (env) polypeptides, antibodies and compositions for treating aids
ATE64601T1 (de) Lymphadenopathie-assoziierte huellenantigene und deren verwendungen.
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
CA2096159A1 (en) Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates
ATE238065T1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
AU668094B2 (en) Seroreactive regions on HPV 16 proteins E1 and E2
BR9500732B1 (pt) kit diagnóstico para a detecção de anticorpos contra vìrus que causam imunodeficiência.
EA200000528A1 (ru) Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией
KR970701062A (ko) 폭스비루스(poxvirus) 성분의 조합에 기초한 파라뮤니티(paramunity) 유발인자(inducer), 그의 제조방법 및 그의 약제에의 이용
NZ506553A (en) Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of hcv viral antigen in host tissue
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
ATE435034T1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.
ATE130198T1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
ATE382696T1 (de) Immunoreaktive antigene des hepatitis e viruses
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
EP0725081A4 (en) MONOCLONAL ANTIBODY AGAINST MxA OF HUMAN Mx PROTEIN
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
AU4948597A (en) Monoclonal antibodies against the ypydvpdya epitope, process for producing the same and their use
DE69333111D1 (de) Natürliche menschliche igm antikörper
WO2000058438A3 (en) Conformationally constrained peptides
SE9600436D0 (sv) Vaccine against hantavirus
ATE192163T1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
PL442478A1 (pl) Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych
Tsekhanovskaia et al. Localization of the antigenic segment of the tick-borne encephalitis virus envelope protein using monoclonal antibodies
EP1013766A3 (en) Peptides for the detection of HIV-1-Group O

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties